- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 19.03. | Terumo Neuro Celebrates 15 Years of the WEB Device: A Game-Changing Innovation in Aneurysm Treatment | 553 | PR Newswire | More than 25,000 Devices Implanted Worldwide from 2010-20251
ALISO VIEJO, Calif., March 19, 2025 /PRNewswire/ -- Terumo Neuro, a global leader in neurovascular innovation and a wholly... ► Artikel lesen | |
| 17.03. | Terumo Co. (OTCMKTS:TRUMY) Sees Significant Increase in Short Interest | 4 | MarketBeat | ||
| TERUMO CORPORATION ADR Aktie jetzt für 0€ handeln | |||||
| 27.02. | Terumo and Daiichi Sankyo partner to support cardiovascular care in Vietnam | 9 | VnExpress | ||
| 14.02. | Terumo (OTCMKTS:TRUMY) Releases Earnings Results | 7 | MarketBeat | ||
| 13.02. | Terumo GAAP EPS of ¥66.51, revenue of ¥772.2B | 6 | Seeking Alpha | ||
| 14.01. | Terumo BCT, FUJIFILM Irvine Scientific Partner on T Cell Expansion Solution | 2 | Contract Pharma | ||
| 10.12.24 | Terumo, Medis announce strategic partnership to enhance cardiovascular care | 5 | MassDevice | ||
| 04.12.24 | Terumo launches R2P NaviCross peripheral support catheter in US | 6 | MassDevice | ||
| 07.11.24 | Terumo reports 1H results | 12 | Seeking Alpha | ||
| 31.10.24 | Terumo BCT Expands Automation Offerings in Latin America | 3 | Contract Pharma | ||
| 16.10.24 | NAMSA und TERUMO kündigen strategische Outsourcing-Partnerschaft an | 354 | Business Wire | Die klinischen Forschungs-, Test- und Beratungsdienste von NAMSA werden dazu beitragen, die behördliche Zulassung des Medizinprodukteportfolios von TERUMO auf globaler Ebene zu beschleunigen. NAMSA... ► Artikel lesen | |
| 15.10.24 | NAMSA and TERUMO Announce Strategic Outsourcing Partnership | 561 | Business Wire | NAMSA's clinical research, testing and consulting services will help accelerate the regulatory approval of TERUMO's medical device portfolio on a global level. NAMSA, a world-leading MedTech... ► Artikel lesen | |
| 13.09.24 | MicroVention firmiert in Terumo Neuro um - Ausdruck eines erweiterten Fokus und strategischen Wachstums | 486 | Business Wire | MicroVention, Inc., ein weltweit führendes Unternehmen im Bereich neurovaskulärer Innovationen und eine hundertprozentige Tochtergesellschaft der Terumo Corporation, gab heute die offizielle Umbenennung... ► Artikel lesen | |
| 12.09.24 | MicroVention Rebrands to Terumo Neuro - Reflects Expanded Focus and Strategic Growth | 499 | Business Wire | MicroVention, Inc., a global leader in neurovascular innovation and a wholly owned subsidiary of Terumo Corporation, today announced its official rebranding to Terumo Neuro, effective immediately.... ► Artikel lesen | |
| 21.08.24 | Terumo-Aktie leicht im Plus (17,05 €) | 466 | ARIVA.de | Die Aktie von Terumo notiert am Mittwoch fester. Das Wertpapier kostete zuletzt 17,05 Euro. Das Wertpapier von Terumo verzeichnet aktuell einen Preisanstieg von 4,92 Prozent. Es hat sich um 80 Cent... ► Artikel lesen | |
| 06.08.24 | Guter Tag für Terumo-Aktionäre: Aktienkurs steigt deutlich (15,15 €) | 477 | ARIVA.de | Zu den großen Gewinnern an der Börse zählt heute das Wertpapier von Terumo . Der Kurs des Anteilsscheins legt kräftig zu. Die Aktie von Terumo gehört heute mit einem Kursplus von 5,94 Prozent zu den... ► Artikel lesen | |
| 06.08.24 | Terumo Corporation: Terumo Establishes Corporate Venture Capital "Terumo Ventures" | 449 | PR Newswire | TOKYO, Aug. 6, 2024 /PRNewswire/ -- Terumo Corporation (TSE: 4543) today announced that it has established "Terumo Ventures," a Corporate Venture Capital (CVC) organization responsible for... ► Artikel lesen | |
| 28.05.24 | Terumo Cardiovascular Announces 510(K) Clearance for the CDI OneView Monitoring System | 304 | PR Newswire | All-new modular, expandable design displays up to 22 vital patient parameters with real-time convenience ANN ARBOR, Mich., May 28, 2024 /PRNewswire/ -- Terumo Cardiovascular, a global leader in... ► Artikel lesen |
18 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MEDTRONIC | 79,87 | -2,48 % | Dividendenbekanntmachungen (28.03.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABERDEEN GROUP PLC ADR US00108N1000 0,3716 USD 0,3442 EUR ACOM CO LTD JP3108600002 7 JPY 0,0429 EUR ADVANEX INC JP3213400009 20... ► Artikel lesen | |
| HCA HEALTHCARE | 306,70 | -4,13 % | Cantor Fitzgerald maintains HCA Healthcare stock at $405 target | ||
| LANTHEUS | 87,80 | -2,23 % | Lantheus Holdings, Inc.: Lantheus Completes Acquisition of Evergreen Theragnostics | BEDFORD, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians... ► Artikel lesen | |
| AMEDISYS | 81,50 | -3,55 % | Amedisys, Inc.: Amedisys Reports Fourth Quarter and Year End 2024 Financial Results | BATON ROUGE, La., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three-month period and year ended December 31, 2024. Three-Month Periods... ► Artikel lesen | |
| ENVISTA | 15,700 | -3,09 % | Envista: DEXIS to Showcase Cutting-Edge Innovations at IDS 2025 | QUAKERTOWN, PENNSYLVANIA / ACCESS Newswire / March 24, 2025 / DEXIS, the global leader in dental imaging technologies, is excited to announce its participation in the International Dental Show (IDS)... ► Artikel lesen | |
| CAREDX | 15,920 | -5,97 % | CareDx, Inc. - 8-K, Current Report | ||
| SYNEOS HEALTH | - | - | Research Solutions, Inc.: Research Solutions Reports Fiscal Second Quarter 2025 Results | Reports 23 Percent Increase in ARR to $19.1 Million and 61 Net New Platform Deployments HENDERSON, Nev., Feb. 13, 2025 /PRNewswire/ -- Research Solutions, Inc. (NASDAQ: RSSS), the leading... ► Artikel lesen | |
| GT BIOPHARMA | 2,400 | 0,00 % | GT Biopharma, Inc.: GT Biopharma to Participate in the 10th Anniversary of the Innate Killer Summit | ||
| CARMAT | 0,869 | +2,24 % | CARMAT - Publication in the JACC(1): Heart Failure of the Initial Clinical Experience with Aeson Total Artificial Heart in Cardiogenic Shock Patients Initially Placed on Extracorporeal Life Support | The retrospective analysis on 10 patients shows a 90% survival rate at 6 months, suggesting Aeson® as a therapeutic solution for these patients at risk of death in the short term.
Regulatory News:
CARMAT... ► Artikel lesen | |
| CHEMOMETEC | 64,00 | -3,98 % | Chemometec A/S: Interim report 2024/25 - Solid H1 performance driven by growth in both revenue and earnings | ANNOUNCEMENT NO. 2875 February 2025 Solid H1 performance driven by growth in both revenue and earnings Martin Helbo Behrens, CEO: The growth continued in the second quarter of 2024/25, and revenue... ► Artikel lesen | |
| HAMILTON THORNE | 1,490 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.12.2024 | The following instruments on Boerse Frankfurt do have their last trading day on 02.12.2024Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.12.2024ISIN NameCA81012R1064 SCOTTIE... ► Artikel lesen | |
| POLAREAN IMAGING | 0,001 | -93,33 % | Polarean Imaging PLC - Expansion of Xenon MRI imaging platform | ||
| ARRAIL GROUP | 0,193 | -2,53 % | ARRAIL GROUP (06639): NEXT DAY DISCLOSURE RETURNS | ||
| DEVYSER DIAGNOSTICS | 9,020 | 0,00 % | Devyser Diagnostics AB: Devyser secures a major SEK 16.8M tender in Italy with 30% growth | Devyser a leading provider of genetic testing solutions, has been awarded a significant tender for the supply of its comprehensive next-generation sequencing (NGS) tests for critical genetic markers.... ► Artikel lesen | |
| PROMIMIC | 2,210 | -9,43 % | Karolinska Development AB (publ): Karolinska Developments portfolio company Promimic publishes positive results on reduction of bacteria growth on HAnano Surface | STOCKHOLM, SWEDEN, February 18 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Promimic has published positive results showing a reduction of bacterial... ► Artikel lesen |
TERUMO CORPORATION ADR gehört der Branche Gesundheitswesen an. Mit einer aktuellen Kursveränderung von -0,400 (-2,44 %) liegt der Kurs bei 16,000 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TERUMO CORPORATION ADR finden Sie auf Wallstreet Online.
